Generics now dominate the semaglutide market worldwide, pushing brand‑name sales into a more limited niche. Industry trackers note that after a rapid rise in India, sales of generic weight‑loss drugs have tapered and overall demand has levelled off. Recent research finds the drug’s weight‑loss effect differs widely between users, with some seeing significant results and others little change. Novo Nordisk announced a partnership with Vivani to create a sustained‑release semaglutide implant that could release the drug over several months. The development aims to give the company a additional option as generic competitors claim more of the market. Analysts say the implant could reshape treatment patterns if clinical trials confirm its safety.